Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Spinal interneurone depression by DS103-282.

D R Curtis, J D Leah, M J Peet

    British Journal of Pharmacology
    |May 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Role of fracture toughness in impact-abrasion wear.

    Wear : an international journal on the science and technology of friction lubrication and wear·2021
    Same author

    CryoEM at 100 keV: a demonstration and prospects.

    IUCrJ·2019
    Same author

    Author Correction: Magnetism and high magnetic-field-induced stability of alloy carbides in Fe-based materials.

    Scientific reports·2018
    Same author

    Magnetism and high magnetic-field-induced stability of alloy carbides in Fe-based materials.

    Scientific reports·2018
    Same author

    The partial primary structure of bovine rhodopsin and its topography in the retinal rod cell disc membrane.

    Neurochemistry international·2010
    Same author

    John Carew Eccles 1903-1997.

    Historical records of Australian science·2007

    The drug DS103-282 reduces nerve excitation in the spinal cord by affecting how signals are received, not released. This finding is crucial for understanding neurotransmitter function and potential therapeutic targets.

    Area of Science:

    • Neuroscience
    • Pharmacology
    • Spinal Cord Physiology

    Background:

    • Polysynaptic excitation in the spinal cord involves complex interneuronal circuits.
    • Understanding drug effects on neuronal excitability is key to developing treatments for neurological disorders.

    Purpose of the Study:

    • To investigate the mechanism of action of 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiodiazole (DS103-282).
    • To determine if DS103-282 affects presynaptic neurotransmitter release or postsynaptic receptor sensitivity.

    Main Methods:

    • Electrophysiological recordings in the cat spinal cord.
    • Assessment of polysynaptic reflexes and interneuronal activity.
    • Distinguishing between pre- and postsynaptic mechanisms.

    Related Experiment Videos

    Main Results:

    • DS103-282 demonstrated a significant depressant effect on polysynaptic excitation.
    • The drug's action was primarily localized to the postsynaptic neuronal membrane.
    • Evidence suggests a reduction in excitatory transmitter effectiveness postsynaptically, not presynaptic release interference.

    Conclusions:

    • DS103-282 modulates spinal cord excitability via postsynaptic mechanisms.
    • The findings highlight the role of postsynaptic targets in mediating the drug's depressant effects.
    • This research provides insights into the neuropharmacology of DS103-282 and spinal interneuronal function.